EGFR and cancer: By monitoring genetic material from cancer cells in the blood, ctDNA analysis offers real-time insights into which mutations are present which helps oncologists determine when to reintroduce anti-EGFR therapies (specifically when resistant mutations are no longer detectable) to maximizes treatment efficacy6.